Navigation Links
Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Date:6/11/2008

s or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development, to expand commercialization activities or consummate acquisitions or to service or repay debt obligations; the accuracy of our estimations of the size of the market, and the potential market, for our products in specific disease areas; sales numbers and future guidance publicly provided by Boston Scientific Corporation regarding sales of their paclitaxel-eluting coronary stent products; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our pate
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. Signalife Provides Corporate Update
5. Biomira Announces Plan to Reincorporate in the United States
6. Pressure BioSciences, Inc. Provides Corporate Update
7. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
8. Clinsys Clinical Research, Inc. Announces Relocation of Corporate Headquarters
9. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by product ... Table-top Counters) by End-user (Inpatient Pharmacy Automation, Outpatient ... 2019” analyzes and studies the major market drivers, ... and the Rest of the World (RoW). , ... through 300 pages and in-depth TOC on "Pharmacy ...
(Date:10/20/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... orders to $5.8 million and provides a good start to Q4.  ... North America and one in the Middle ... at record levels," said Peter Bruijns , President & CEO. ... of Q3 than they have been for any complete year since ...
(Date:10/20/2014)... PLAINSBORO, N.J. (PRWEB) October 20, 2014 ... that the Sidney Kimmel Cancer Center at Thomas ... program. , Through the Strategic Alliance Partnership ... and OncLive will collaborate to raise awareness of ... cancer treatment, and other projects. Clinicians and other ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... Conn., Aug. 25, 2011 Advanced BioHealing, ... medicine therapies, today announced that it ranked in the ... list of America,s fastest-growing, privately held companies. ... at a vital segment of the U.S. economy—America,s independent-minded ...
... major impact on future nanoscale device design, such as ... size, many materials like silicon are as brittle as ... compressed into half their size without breaking them. The ... led by Professor Roman Nowak. Atom by atom, ...
... Aug. 24, 2011 Bacterin International Holdings, Inc. ... development of revolutionary bone graft material and antimicrobial coatings for ... Nicolaus 2011 Healthcare Conference. The conference will be held at ... 2011. Bacterin,s chairman and CEO, Guy Cook, and ...
Cached Biology Technology:Advanced BioHealing Named to Prestigious Inc. 500 List of America's Fastest Growing Private Companies 2Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011 2
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
(Date:10/16/2014)... have a new synthesis of recent research findings to ... in the two states. , The Ecology and ... Washington: A Synthesis of the Relevant Biophysical Science and ... published by the U.S. Forest Service,s Pacific Northwest Research ... managers for a synthesis of the large body of ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... causes those painful lip blisters known as cold sores has an ... it to literally blast its infectious DNA into human cells, scientists ... mechanism the first in a human virus opens the ... study in the Journal of the American Chemical Society . ...
... revealed new images which provide the clearest picture yet ... and tumours. , They show how the cells, which ... human body, change the organisation of their surface molecules, ... viral-infected or tumour cells., Professor Daniel Davis, who has ...
... HUNTSVILLE, Ala -- Even in the absence of a ... and intellectual challenges is helpful to physicians and families. ... high throughput genomic sequencing to meet major diagnostic needs ... totaling more than $7.6 million from the National Institutes ...
Cached Biology News:Researchers reveal the clearest new pictures of immune cells 2HudsonAlpha awarded grant to improve diagnoses of childhood genetic disorders 2
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
... polyclonal NPY Y2 Receptor antiserum This ... the spinal level and is currently being characerized ... both rat and mouse and appears to work ... seen in rat. For full characterizarion in dorsal ...
RECK (F-20)...
Black Polypropylene 384 Round Well Plate 70/Box...
Biology Products: